Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash from Investing Activities: 2011-2024

Historic Cash from Investing Activities for Assembly Biosciences (ASMB) over the last 14 years, with Dec 2024 value amounting to $40.2 million.

  • Assembly Biosciences' Cash from Investing Activities fell 746.32% to -$158.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$141.4 million, marking a year-over-year decrease of 230.44%. This contributed to the annual value of $40.2 million for FY2024, which is 158.10% up from last year.
  • According to the latest figures from FY2024, Assembly Biosciences' Cash from Investing Activities is $40.2 million, which was up 158.10% from -$69.1 million recorded in FY2023.
  • Assembly Biosciences' 5-year Cash from Investing Activities high stood at $90.6 million for FY2022, and its period low was -$69.1 million during FY2023.
  • Moreover, its 3-year median value for Cash from Investing Activities was $40.2 million (2024), whereas its average is $20.6 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 241.84% in 2022, then plummeted by 176.28% in 2023.
  • Yearly analysis of 5 years shows Assembly Biosciences' Cash from Investing Activities stood at $68.1 million in 2020, then tumbled by 61.05% to $26.5 million in 2021, then surged by 241.84% to $90.6 million in 2022, then plummeted by 176.28% to -$69.1 million in 2023, then spiked by 158.10% to $40.2 million in 2024.